

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

ELECTION OF THE SUPERVISOR REPRESENTING THE EMPLOYEES OF THE 9TH SESSION OF THE SUPERVISORY COMMITTEE

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) announces that at the enlarged meeting of the 5th session of the labour union committee of the Company held on 25 April 2023, Mr. Jian Huidong (“**Mr. Jian**”), the exiting supervisor representing the shareholders, was elected as the supervisor representing the employees of the 9th session of the supervisory committee of the Company. Set out below is the information on Mr. Jian.

PERSONAL PARTICULARS

Mr. Jian Huidong, aged 50 and holds a bachelor degree and senior corporate cultural division title. Mr. Jian began to work in July 1994, has since served as vice chairperson of labor union of Guangzhou Pharmaceutical Holdings Limited (“**GPHL**”) and vice chairperson of labor union of headquarter of GPHL. Mr. Jian has been a supervisor of the Company since 3 June 2021, and currently serves as vice chairperson of labor union of the Company and vice chairperson of labor union of headquarter of the Company. Mr. Jian has worked for the labor union for many years and has rich experience in employee services, protection of employee rights and interests, and targeted poverty alleviation.

TERMS OF OFFICE

The term of office of Mr. Jian as a member of the 9th session of the supervisory committee shall be the same with those members of the 9th session of the supervisory committee to be elected at the 2022 annual general meeting (“**AGM**”) of the Company. On this basis, it is expected that the term of office of Mr. Jian as a member of the 9th session of the supervisory committee of the Company will be approximately three years. The Company will enter into a service agreement with Mr. Jian.

REMUNERATION

Since Mr. Jian was also the vice chairperson of the labor union of the Company, the emoluments payable to him for year 2023 are estimated to be not exceeding RMB750,000, including but not limited to the basic salary, welfare benefits as well as settlement of annual salary for the previous year, etc. The actual emoluments shall also be assessed and adjusted in accordance with the Compensation and Performance Appraisal Measures for Senior Management of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited. The said emoluments are emoluments before tax and the individual income tax payable shall be withheld and paid by the Company. The term of office of Mr. Jian as a member of the 9th session of the supervisory committee shall be the same with those members of the 9th session of the supervisory committee to be elected at the AGM of the Company. The emoluments payable to Mr. Jian for year 2023 shall be determined with reference to the actual period of service and employment status in 2023.

INTERESTS IN THE SHARES OF THE COMPANY WITHIN THE MEANING OF PART XV OF THE SFO

None of Mr. Jian or any of his associates has, or is deemed to have, any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (“SFO”).

NO OTHER INFORMATION REQUIRED TO BE DISCLOSED

Save as disclosed in the preceding sections of this announcement, as at the date of this announcement, Mr. Jian:

- (a) does not have any relationship with any directors of the Company, other supervisors of the Company, senior management or substantial or controlling shareholders of the Company;
- (b) has not held any directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas;
- (c) does not hold any position in the Company or the subsidiaries of the Company; and
- (d) does not have other matters that need to be brought to the attention of the shareholders of the Company and there is no information required to be disclosed pursuant to the requirements of Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The other two supervisors representing the shareholders of the supervisory committee of the Company will be elected at the AGM of the Company to be held on 30 May 2023 and a circular containing detailed information in relation thereto will be dispatch to shareholders on 26 April 2023.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 25 April 2023

As at the date of this announcement, the Board comprises Mr. Li Chuyuan, Mr. Yang Jun, Ms. Cheng Ning, Ms. Liu Juyan, Mr. Zhang Chunbo, Mr. Wu Changhai and Mr. Li Hong as executive directors, and Mr. Wong Hin Wing, Ms. Wang Weihong, Mr. Chen Yajin, and Mr. Huang Min as independent non-executive directors.